Description

This Drug Discovery TOE depicts trends across biopharmaceuticals for psoriasis, hepatocellular carcinoma, Crohn's disease, migraine, HIV, and hepatitis B infection, among others. Clinical trial analysis of Etanercept biosimilar is also presented.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Biopharmaceuticals, FDA-approved drugs, psoriasis treatment, Ramucirumab, hepatocellular carcinoma, monoclonal antibody, Crohn’s disease, calcitonin gene-related peptide, drug targets, migraine prevention, multi-drug resistant HIV infection, biologics manufacturing, biosimilar commercialization, X-linked hypophosphatemia, immunotherapy, hepatitis B